Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Duncan J. Topliss, Luís M. Ruilope et al.|Diabetes Care|2022Cited by 207
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trialHiddo J.L. Heerspink, Bi‐Cheng Liu, Rajiv Agarwal et al.|Nephrology Dialysis Transplantation|2024Cited by 83